522.27
+10.35(+2.02%)
Currency In USD
| Previous Close | 511.92 |
| Open | 515.79 |
| Day High | 527.47 |
| Day Low | 515.79 |
| 52-Week High | 1,211.2 |
| 52-Week Low | 476.49 |
| Volume | 970,277 |
| Average Volume | 1.36M |
| Market Cap | 55.44B |
| PE | 13.27 |
| EPS | 39.35 |
| Moving Average 50 Days | 556.75 |
| Moving Average 200 Days | 737.78 |
| Change | 10.35 |
If you invested $1000 in Regeneron Pharmaceuticals, Inc. (REGN) 10 years ago, it would be worth $1,005.84 as of June 25, 2025 at a share price of $522.27. Whereas If you bought $1000 worth of Regeneron Pharmaceuticals, Inc. (REGN) shares 5 years ago, it would be worth $842.43 as of June 25, 2025 at a share price of $522.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
GlobeNewswire Inc.
Yesterday at 11:30 AM GMT
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medicationsTARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the launch of a pi
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
GlobeNewswire Inc.
Jun 02, 2025 11:05 AM GMT
New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially similar profile to the only FDA-approved GLP-1/GIP receptor
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
GlobeNewswire Inc.
May 30, 2025 5:00 AM GMT
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit AERIFY-2, a second Phase 3 trial,